{"news_desk": "Business", "print_page": "9", "section_name": "Business Day", "subsection_name": "DealBook", "byline": {"original": "By ANDREW POLLACK", "person": [{"rank": 1, "role": "reported", "firstname": "Andrew", "organization": "", "lastname": "POLLACK"}]}, "abstract": "Alexion Pharmaceuticals says it will buy Synageva BioPharma for about $8.4 billion; firm specializes in rare diseases, with new drug launching in 2015.", "type_of_material": "News", "word_count": "727", "lead_paragraph": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "pub_date": "2015-05-07T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Alexion\u00a0to Buy Synageva BioPharma in $8.4 Billion Deal", "print_headline": "Alexion, Maker of a Rare-Disease Drug, Buys Another"}, "snippet": "The deal taps into the interest for so-called orphan drugs, where companies can charge hundreds of thousands of dollars a year to treat rare diseases.", "multimedia": [{"height": 126, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 422, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "422", "xlarge": "images/2015/05/07/business/07db-drug-web/07db-drug-web-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/05/07/business/07db-drug-web/07db-drug-web-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/05/07/business/dealbook/alexion-to-buy-synageva-biopharma-in-8-4-billion-deal.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Alexion Pharmaceuticals Inc", "name": "organizations"}, {"rank": "2", "is_major": "Y", "value": "Synageva BioPharma Corp", "name": "organizations"}, {"rank": "3", "is_major": "N", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Biotechnology and Bioengineering", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Mergers, Acquisitions and Divestitures", "name": "subject"}], "blog": [], "_id": "554a2ed738f0d838fba7397c", "source": "The New York Times"}